Skip to Content
Merck
  • Ceramide Transporter CERT Is Involved in Muscle Insulin Signaling Defects Under Lipotoxic Conditions.

Ceramide Transporter CERT Is Involved in Muscle Insulin Signaling Defects Under Lipotoxic Conditions.

Diabetes (2018-05-16)
Cécile L Bandet, Rana Mahfouz, Julien Véret, Athanassia Sotiropoulos, Maxime Poirier, Paola Giussani, Mélanie Campana, Erwann Philippe, Agnieszka Blachnio-Zabielska, Raphaëlle Ballaire, Xavier Le Liepvre, Olivier Bourron, Dušan Berkeš, Jan Górski, Pascal Ferré, Hervé Le Stunff, Fabienne Foufelle, Eric Hajduch
ABSTRACT

One main mechanism of insulin resistance (IR), a key feature of type 2 diabetes, is the accumulation of saturated fatty acids (FAs) in the muscles of obese patients with type 2 diabetes. Understanding the mechanism that underlies lipid-induced IR is an important challenge. Saturated FAs are metabolized into lipid derivatives called ceramides, and their accumulation plays a central role in the development of muscle IR. Ceramides are produced in the endoplasmic reticulum (ER) and transported to the Golgi apparatus through a transporter called CERT, where they are converted into various sphingolipid species. We show that CERT protein expression is reduced in all IR models studied because of a caspase-dependent cleavage. Inhibiting CERT activity in vitro potentiates the deleterious action of lipotoxicity on insulin signaling, whereas overexpression of CERT in vitro or in vivo decreases muscle ceramide content and improves insulin signaling. In addition, inhibition of caspase activity prevents ceramide-induced insulin signaling defects in C2C12 muscle cells. Altogether, these results demonstrate the importance of physiological ER-to-Golgi ceramide traffic to preserve muscle cell insulin signaling and identify CERT as a major actor in this process.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
HPA-12, ≥98% (HPLC)